The American Journal of Managed Care3d
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...
The American Journal of Managed Care7d
CROI to Present New Insights on Long COVID Risk, HIV Cure
One of the hot topics at this year's Conference on Retroviruses and Opportunistic Infections will be long COVID: potential ...
A Pill to Prevent COVID-19 Shows Promise
That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...
Healio9h
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
El Mundo on MSN2d
New advance against HIV: a single annual injection against the infection
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
aidsmap10d
aidsmap returns with reporting from the Conference on Retroviruses and Opportunistic Infections (CROI)
News reporting will resume with coverage of the Conference on Retroviruses and Opportunistic Infections (CROI), being held in San Francisco from 9 to 12 March. Our reporting team from CROI are Keith ...
Study examines a novel way to bring addiction care and HIV prevention to people who inject drugs
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Managed Healthcare Executive1d
If Twice-Yearly Lenacapavir Could Be a HIV PrEP Game Changer, Would a Once-Yearly Version Be a HIV Epidemic Ender?
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Bay Area Reporter2d
At CROI conference, HIV activists sound alarm on Trump policies
AIDS advocates are fearful that budget cuts being pushed by Republicans will gut essential health care services in the United ...
Gilead Presents New HIV Treatment And Cure Research Data
Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...
Healio11h
Long-acting treatment benefits postpartum women with HIV and their babies
Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...